Want to see SEER full AI Analyst Report?
Top Page
Seer
(NASDAQ:SEER)
Select Model
Select Model
Rating:51Neutral
Price Target:
$2.00
▲(1.52% Upside)
Action:Reiterated
Date:07/29/26
Overall score is held back primarily by weak financial performance (ongoing losses and cash burn despite improved expense discipline) and limited valuation support (negative P/E with no dividend yield provided). Offsetting factors include a constructive price trend above key moving averages and an earnings call that reaffirmed guidance while highlighting strong liquidity and cost reductions, though near-term revenue and margin pressures remain significant.
Positive Factors
Strong cash runway and low leverage
A cash balance of ~$219.5M combined with very low debt (debt/equity ~0.07–0.10) gives Seer durable financial flexibility. This funding runway supports continued R&D, commercialization investments and share repurchases while reducing near-term dilution risk and enabling time to scale consumable pull-through.
Negative Factors
Persistent negative operating and free cash flow
Continued negative operating and free cash flow indicates ongoing cash burn despite improvements. Reliance on cash reserves or external financing to fund operations compresses optionality, can delay break‑even timing and increases the risk that future scaling or commercialization investments are constrained if cash generation lags expectations.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash runway and low leverage
A cash balance of ~$219.5M combined with very low debt (debt/equity ~0.07–0.10) gives Seer durable financial flexibility. This funding runway supports continued R&D, commercialization investments and share repurchases while reducing near-term dilution risk and enabling time to scale consumable pull-through.
Read all positive factors
Seer (SEER) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$122.80M
Dividend YieldN/A
Average Volume (3M)113.15K
Price to Earnings (P/E)―
Beta (1Y)1.41
Revenue Growth-1.44%
EPS Growth11.50%
CountryUS
Employees124
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.24
Shares Outstanding55,315,983
10 Day Avg. Volume70,395
30 Day Avg. Volume113,152
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.41
Price to Sales (P/S)6.52
P/FCF Ratio-2.27
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.00Price Target Upside103.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$16.15M
Seer Business Overview & Revenue Model
Company Description
null...
How the Company Makes Money
null...
Seer Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call balanced clear short-term commercial and margin headwinds (33% YoY revenue decline, compressed gross margin to 35%, negative free cash flow) with multiple strategic positives: rapidly expanding scientific validation (publications doubled YoY), major population-scale biobank partnerships (PRECISE-SG100K and others), continued product and analytics innovation (SP200, Proteograph One Assay, next-gen detector, Raviant DIA), meaningful operating expense reductions (~20% YoY), improved net loss, strong cash position ($219.5M) and active share repurchases. Management reaffirmed full-year guidance and is taking defensive IP/legal actions against imitators while adding seasoned commercial leadership to drive commercialization. Overall, the call signals durable long-term opportunity and disciplined financial management but acknowledges near-term revenue and margin pressures.Positive Updates
Rapid Growth in Peer-Reviewed Validation
Publications validating the Proteograph product suite reached 84 (vs. 42 as of March 2025 and 3 in 2022), effectively doubling year-over-year (~+100% YoY) and strengthening scientific credibility.
Negative Updates
Significant Revenue Decline in Q1
Total Q1 2026 revenue was $2.8M versus $4.2M in Q1 2025, a decline of $1.4M or ~33% year-over-year, driven by depressed academic funding, increased competitive activity from imitators, and commercial transition timing.
Read all updates
Q1-2026 Updates
Positive
Negative
Rapid Growth in Peer-Reviewed Validation
Publications validating the Proteograph product suite reached 84 (vs. 42 as of March 2025 and 3 in 2022), effectively doubling year-over-year (~+100% YoY) and strengthening scientific credibility.
Read all positive updates
Company Guidance
Seer reaffirmed full‑year 2026 revenue guidance of $16.0–$18.0 million (about 3% growth at the midpoint versus 2025) despite a soft Q1 when total revenue was $2.8M (product $2.1M; services $0.6M, including $0.1M related‑party; other $0.1M). Q1 gross profit was roughly $1.0M (35% gross margin vs. 49% in Q1 2025), while management reiterated long‑term gross margin targets of 70–75% and cautioned quarter‑to‑quarter variability driven by instrument/consumable mix. Operating expenses fell to $18.2M in Q1 (including $2.1M stock‑based comp) from $22.8M a year ago (including $4.5M), with R&D $8.8M and SG&A $9.4M; net loss narrowed to $16.8M and free cash flow was about -$15.7M. The company ended the quarter with ~$219.5M in cash, cash equivalents and investments, has repurchased ~13.2M shares to date (Q1: ~1.5M at an average $1.78; VWAP $1.86, ~$24.5M of a $25M program) and says it has sufficient capital to reach cash‑flow breakeven, expecting instrument utilization and consumable pull‑through to build (primarily in the back half) even as NIH funding headwinds and market imitators create near‑term uncertainty.Seer Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
62
Positive
Cash Flow
31
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.68M | 16.12M | 13.95M | 15.18M | 14.69M | 6.39M |
| Gross Profit | 6.90M | 8.01M | 6.83M | 1.45M | 384.00K | -374.00K |
| EBITDA | -68.48M | -71.89M | -80.33M | -80.70M | -87.06M | -67.61M |
| Net Income | -70.49M | -73.60M | -86.60M | -86.28M | -92.97M | -71.17M |
Balance Sheet | ||||||
| Total Assets | 272.13M | 296.08M | 366.60M | 436.27M | 487.93M | 539.14M |
| Cash, Cash Equivalents and Short-Term Investments | 166.67M | 185.90M | 236.41M | 316.22M | 421.24M | 400.07M |
| Total Debt | 23.03M | 23.65M | 25.96M | 28.26M | 29.87M | 23.32M |
| Total Liabilities | 30.65M | 36.78M | 39.03M | 39.37M | 40.94M | 36.22M |
| Stockholders Equity | 241.48M | 259.31M | 327.57M | 396.90M | 446.99M | 502.92M |
Cash Flow | ||||||
| Free Cash Flow | -49.88M | -46.24M | -49.69M | -66.37M | -71.05M | -53.27M |
| Operating Cash Flow | -48.47M | -44.45M | -46.11M | -59.06M | -60.78M | -46.35M |
| Investing Cash Flow | 55.01M | 61.55M | 65.86M | 37.90M | -122.72M | -170.88M |
| Financing Cash Flow | -11.67M | -10.57M | -11.49M | 452.00K | 3.89M | 116.63M |
Seer Technical Analysis
Positive
1.97
Price Trends
1.92
Positive
1.87
Positive
1.91
Positive
Market Momentum
0.07
Negative
61.44
Neutral
93.80
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEER, the sentiment is Positive. The current price of 1.97 is below the 20-day moving average (MA) of 2.13, above the 50-day MA of 1.92, and above the 200-day MA of 1.91, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 61.44 is Neutral, neither overbought nor oversold. The STOCH value of 93.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SEER.
Seer Risk Analysis
Seer disclosed 66 risk factors in its most recent earnings report. Seer reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Seer Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $287.83M | -4.04 | -41.31% | ― | ― | 73.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $122.80M | -1.79 | -26.58% | ― | -1.44% | 11.50% | |
49 Neutral | $79.62M | -3.40 | -72.68% | ― | ― | 64.57% | |
44 Neutral | $48.29M | -1.01 | -39.76% | ― | ― | 40.85% | |
44 Neutral | $48.56M | -0.77 | -91.94% | ― | 106.65% | 12.20% | |
42 Neutral | $257.87M | -0.54 | 309.79% | ― | -35.61% | -68.92% |
* Healthcare Sector Average
SEER
Seer
2.21
0.09
4.25%
IKT
Inhibikase Therapeutics
2.44
0.64
35.56%
SRZN
Surrozen
22.00
11.60
111.54%
TIL
Instil Bio
7.25
-19.74
-73.14%
TCRX
TScan Therapeutics
0.74
-1.01
-57.94%
CGTX
Cognition Therapeutics
0.99
0.27
36.94%
Seer Corporate Events
Business Operations and StrategyM&A Transactions
Seer Board Rejects CEO’s Undervalued Takeover Proposal
Positive
Jul 20, 2026
On July 20, 2026, Seer, Inc. announced that a special committee of its board, composed of independent directors, had unanimously rejected an unsolicited, non-binding offer from Chair and CEO Omid Farokhzad dated July 1, 2026. The proposal sought t...
Business Operations and StrategyM&A Transactions
Seer CEO Makes Insider Proposal to Take Company Private
Neutral
Jul 2, 2026
On July 2, 2026, Seer, Inc. announced it had received an unsolicited, non-binding proposal from its chair and chief executive officer, Omid Farokhzad, M.D., to acquire all outstanding shares of the company’s Class A common stock for $2.45 pe...
Business Operations and StrategyM&A TransactionsRegulatory Filings and ComplianceShareholder Meetings
Seer Board Rejects Revised Radoff-JEC Acquisition Proposal
Neutral
May 22, 2026
On May 21, 2026, Seer, Inc. announced that its board of directors unanimously rejected a further revised unsolicited, non-binding acquisition proposal submitted on May 14, 2026, by the Radoff-JEC Group to buy all outstanding Class A shares for $2....
Business Operations and StrategyExecutive/Board Changes
Seer Appoints Anthony Bazarko as Chief Commercial Officer
Positive
May 4, 2026
On May 4, 2026, Seer, Inc., a Nasdaq-listed life sciences tools company specializing in deep, unbiased proteomics, announced the appointment of veteran commercial executive Anthony Bazarko as Chief Commercial Officer. Seer develops and markets the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.